English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Objective: Leishmaniasis is one of the common forms of neglected parasitic disease that causes a worldwide disease burden without any specified therapeutic system available. The control strategy relies on chemotherapy and most available drugs have toxic side-effects and drug-resistant strains have emerged. So, the development of new therapeutic strategies to treat patients for leishmaniasis has become a priority. The first step in drug discovery is to identify an effective drug target by different methods such as system biology. Protein kinases represent promising drug targets for different diseases. Due to lack of a functional krebs cycle in Leishmania species, they use glycolysis as the only source of ATP generation. Pyruvate kinase is the enzyme involved in the last step of glycolysis and considered as essential enzyme for the Leishmania survival. Materials and Methods: The study deals with discovery of FDA approved compounds against the leishmanial pyruvate kinase protein. We have taken a quantitative proteomics, protein interaction network and docking approach to the detection of new drug targets and potent inhibitors. u co rre ct d roo f

turkish journal of pharmaceutical sciences

Discovery of Novel Pyruvate Kinase Inhibitors Against &lt;i&gt;Leishmania major&lt;/i&gt; Among FDA Approved Drugs Through System Biology and Molecular Docking Approach